Invizyne Technologies Stock (NASDAQ:IZTC)


FinancialsChart

Previous Close

$15.50

52W Range

$8.50 - $23.99

50D Avg

$15.57

200D Avg

$14.78

Market Cap

$157.23M

Avg Vol (3M)

$37.03K

Beta

-4.51

Div Yield

-

IZTC Company Profile


Invizyne Technologies Inc. is an American synthetic biochemical company that has developed SimplePath, an innovative platform. This technology is designed to synthesize a diverse range of chemicals, including vital substances like pharmaceuticals, fuels, and advanced materials, as well as food additives and entirely novel compounds. At its core, SimplePath is composed of specialized modules, each integrating one or more enzymes that collaboratively execute defined biocatalytic conversions. Established in 2014, Invizyne Technologies' operations are headquartered in Monrovia, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Nov 13, 2024

Website

IZTC Performance


IZTC Financial Summary


Dec 24
Revenue-
Operating Income-
Net Income$-5.86M
EBITDA-
Basic EPS$-0.89
Diluted EPS$-0.89

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
THTXTheratechnologies Inc.
QNRXQuoin Pharmaceuticals, Ltd.
ATYRaTyr Pharma, Inc.
LENZLENZ Therapeutics, Inc.